Skip to content

LNTH

NASDAQ

Lantheus Holdings Inc

Health Care
Health Care

$100.33

0.1%

Updated Today 11:10 AM ET

Report Card

LNTH at a glance — five pillars scored 0–100 from real filed financials.

Value
Growth
Profitability
0
Health
0
Dividends
0

Overall: Unrated · 0/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.

Key Metrics

Market Cap

$0.00

P/E

Forward P/E (est.)

ROE

Revenue Growth

EPS Growth

Profit Margin

FCF Yield

Debt / Equity

ROIC

13.0%

Interest Coverage

15.53x

Current Ratio

3.06x

Dividend Yield

Implied Growth (rev. DCF)

Rating Score

0/100

Business Overview
Research

Lantheus Holdings Inc (LNTH) is a small-cap company in the Health Care industry, part of the Health Care sector of the S&P 500.

In its latest reported year it generated about $1.54B in revenue and $233.56M in net profit.

Our model rates LNTH Unrated (0/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.

Economic Moat

Evidence of durable competitive advantage in the filed financials (9 years of history).

Narrow moat signalsMoat evidence score: 68/100

Some durable-advantage evidence, but not across the board — dig into which ingredient is weak and whether it's cyclical or structural.

Gross margin level100/100

60.1% average over the last 3 years

Gross margin stability3/100

±7.7 pts around 53.1% across 9 years

Revenue durability86/100

grew in 7 of the last 8 year-over-year periods

Free-cash-flow consistency100/100

positive in 9 of 9 years

Return on invested capital40/100

13.0% latest fiscal year

A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.

Revenue Growth
Research

4Y CAGR

38.0%

Revenue moved from $331.38M in 2017 to $1.54B in 2025, a 21.2% compound annual growth rate. The most recent year was roughly steady year over year. Slower, mature growth is common for established businesses.

Profitability
1/1 checks passedROIC above 10%

Gross Margin

61.1%

Operating Margin

20.2%

Net Margin

15.2%

ROE

Debt Analysis
Research
2/2 checks passedInterest covered 3×+Short-term bills covered

Total Debt

$558.07M

Net Debt

-$35.23M

Net cash position

Net Debt / EBITDA

-0.11x

Debt / Equity

Leverage: debt-to-equity is n/a, and operating profit covers interest about 15.5x, with a current ratio of 3.1x. Detailed balance-sheet leverage is limited for this name. It carries roughly $558.07M of total debt against $593.30M of cash.

Cash Flow Analysis
Research

Operating CF

$390.14M

Free Cash Flow

$354.05M

FCF Margin

23.0%

In the latest year Lantheus Holdings Inc produced about $390.14M of operating cash flow and $354.05M of free cash flow after capital spending. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.

Valuation Analysis
Research
0/1 checks passedTrading below DCF fair value

P/E

P/S

P/B

EV / EBITDA

LNTH trades at n/a trailing earnings. With no positive trailing earnings, value it on sales, cash flow, or growth rather than P/E.

DCF Fair Value (Educational)

A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.

DCF fair value / share

$93.13

Current price

$100.33

-7% · Near fair-value estimate

Starting FCF (latest 10-K)

$354.05M

Growth, years 1–5

4.0%

Fade to terminal, years 6–10

2.5%

Discount rate

9.0%

PV of 10-yr free cash flow$2.74B
PV of terminal value$3.34B
Estimated equity value$6.08B
Shares outstanding65M

Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.

Metrics vs. Sector Range

Where LNTH sits versus its Health Care sector peers in the S&P 500.

TTM P/E
Forward P/E
P/S ratio
Revenue growth
EPS growth
Gross margin
61.1%Average
Net margin
ROE

Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.

Sector Peer Comparison

How LNTH stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.

In the Health Care sector (324 S&P 500 companies), LNTH ranks #211 of 324 by our overall rating.

P/E vs sector

median 27.3x

ROE vs sector

median 14.1%

Growth vs sector

median 7.6%

Sector rank

#211

of 324 by rating

CompanyP/ERev Gr.Rating
LNTHThis stockNot rated
ACHCNot rated
ADUSNot rated
AHCONot rated
ALHCNot rated
ASSTNot rated
ASTHNot rated
ATECNot rated
Health Care median27.3x7.6%0/100
Compare side by side

Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 324 S&P 500 names in the sector. Educational, not a recommendation.

5-Year Projection Model

Project revenue → earnings → price. Edit the assumptions to build your own case.

2030 price target (Base Case)

$0.00 $0.00

vs. $100.33 today · expected CAGR -9%1%

Metric20262027202820292030
Revenue$1.66B$1.80B$1.94B$2.10B$2.27B
Net income$249.74M$269.72M$291.30M$314.60M$339.77M
EPS$3.83$4.13$4.46$4.82$5.21
Share price (low)$45.91$49.59$53.55$57.84$62.46
Share price (high)$76.52$82.64$89.26$96.40$104.11
CAGR (low–high)-54% / -24%-30% / -9%-19% / -4%-13% / -1%-9% / 1%

Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.

Bull Case

The case for LNTH:

  • As an established S&P 500 member in Health Care, it brings scale and a long operating history.
Bear Case

The case against LNTH:

  • Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Key Risks
Research

Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.

Investment Thesis
Research

On balance, the picture is mixed: Lantheus Holdings Inc is a small-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at n/a earnings, which our model scores Unrated (0/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.

Latest SEC Filings

LNTH's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.

LNTH — frequently asked questions

Is LNTH a good stock to buy?

We don't give buy or sell advice. Review Lantheus Holdings Inc's fundamentals, valuation, and 5-year financials on this page, then make your own decision — and consider a licensed professional.

Where does LNTH's data come from?

Live price data plus real fundamentals and 5-year financials pulled directly from Lantheus Holdings Inc's SEC filings — refreshed automatically, not hand-entered.

How is the 5-year projection for LNTH calculated?

It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.

Is this LNTH analysis financial advice?

No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell LNTH. Always do your own research and consider a licensed professional.

Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.

Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.